93 related articles for article (PubMed ID: 15837333)
1. The development of new isoxazolone based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Laughlin SK; Clark MP; Djung JF; Golebiowski A; Brugel TA; Sabat M; Bookland RG; Laufersweiler MJ; VanRens JC; Townes JA; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2399-403. PubMed ID: 15837333
[TBL] [Abstract][Full Text] [Related]
2. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
Townes JA; Golebiowski A; Clark MP; Laufersweiler MJ; Brugel TA; Sabat M; Bookland RG; Laughlin SK; VanRens JC; De B; Hsieh LC; Xu SC; Janusz MJ; Walter RL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4945-8. PubMed ID: 15341957
[TBL] [Abstract][Full Text] [Related]
3. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
4. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Clark MP; Laughlin SK; Laufersweiler MJ; Bookland RG; Brugel TA; Golebiowski A; Sabat MP; Townes JA; VanRens JC; Djung JF; Natchus MG; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Heitmeyer SA; Brown KK; Juergens K; Taiwo YO; Janusz MJ
J Med Chem; 2004 May; 47(11):2724-7. PubMed ID: 15139749
[TBL] [Abstract][Full Text] [Related]
5. Development of N-2,4-pyrimidine-N-phenyl-N'-phenyl ureas as inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 1.
Brugel TA; Maier JA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3510-3. PubMed ID: 16632356
[TBL] [Abstract][Full Text] [Related]
6. The development of novel C-2, C-8, and N-9 trisubstituted purines as inhibitors of TNF-alpha production.
Sabat M; Vanrens JC; Clark MP; Brugel TA; Maier J; Bookland RG; Laufersweiler MJ; Laughlin SK; Golebiowski A; De B; Hsieh LC; Walter RL; Mekel MJ; Janusz MJ
Bioorg Med Chem Lett; 2006 Aug; 16(16):4360-5. PubMed ID: 16750367
[TBL] [Abstract][Full Text] [Related]
7. Development of N-2,4-pyrimidine-N-phenyl-N'-alkyl ureas as orally active inhibitors of tumor necrosis factor alpha (TNF-alpha) synthesis. Part 2.
Maier JA; Brugel TA; Clark MP; Sabat M; Golebiowski A; Bookland RG; Laufersweiler MJ; Laughlin SK; Vanrens JC; De B; Hsieh LC; Brown KK; Juergens K; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2006 Jul; 16(13):3514-8. PubMed ID: 16632350
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
9. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
Laufersweiler MJ; Brugel TA; Clark MP; Golebiowski A; Bookland RG; Laughlin SK; Sabat MP; Townes JA; VanRens JC; De B; Hsieh LC; Heitmeyer SA; Juergens K; Brown KK; Mekel MJ; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4267-72. PubMed ID: 15261284
[TBL] [Abstract][Full Text] [Related]
10. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells.
Grund EM; Kagan D; Tran CA; Zeitvogel A; Starzinski-Powitz A; Nataraja S; Palmer SS
Mol Pharmacol; 2008 May; 73(5):1394-404. PubMed ID: 18252806
[TBL] [Abstract][Full Text] [Related]
14. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
15. Suppression of lipopolysaccharide-induced cytokine production of gingival fibroblasts by a soybean, Kunitz trypsin inhibitor.
Kobayashi H; Yoshida R; Kanada Y; Fukuda Y; Yagyu T; Inagaki K; Kondo T; Kurita N; Suzuki M; Kanayama N; Terao T
J Periodontal Res; 2005 Dec; 40(6):461-8. PubMed ID: 16302924
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction.
Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J
J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068
[TBL] [Abstract][Full Text] [Related]
17. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.
Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR
J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structure-activity relationship of coumarin derivatives as TNF-alpha inhibitors.
Cheng JF; Chen M; Wallace D; Tith S; Arrhenius T; Kashiwagi H; Ono Y; Ishikawa A; Sato H; Kozono T; Sato H; Nadzan AM
Bioorg Med Chem Lett; 2004 May; 14(10):2411-5. PubMed ID: 15109623
[TBL] [Abstract][Full Text] [Related]
19. A novel series of p38 MAP kinase inhibitors for the potential treatment of rheumatoid arthritis.
Brown DS; Belfield AJ; Brown GR; Campbell D; Foubister A; Masters DJ; Pike KG; Snelson WL; Wells SL
Bioorg Med Chem Lett; 2004 Nov; 14(21):5383-7. PubMed ID: 15454231
[TBL] [Abstract][Full Text] [Related]
20. The development of new triazole based inhibitors of tumor necrosis factor-alpha (TNF-alpha) production.
Tullis JS; VanRens JC; Natchus MG; Clark MP; De B; Hsieh LC; Janusz MJ
Bioorg Med Chem Lett; 2003 May; 13(10):1665-8. PubMed ID: 12729637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
